AUTHOR INDEX Aalders JG, see de Hullu JA Akard L. Optimum Methods to Mobilize Stem Cells (correspondence), Aaltonen LA, see Salovaara R 3063 Aamdal S, see Middleton MR Akard LP, see Fife BL Aaron D, see Boon H Akasaka H, see Akasaka T Aaronson N, see Middleton MR Akasaka T, Akasaka H, Ueda C, Yonetani N, Maesako Y, Shimizu A, Aaronson NK, see Detmar SB Yamabe H, Fukuhara S, Uchiyama T, Ohno H. Molecular —see Lonning PE and Clinical Features of Non-Burkitt’s, Diffuse Large-Cell Abbasciano V, see Sartori S Lymphoma of B-Cell Type Associated with the c-MYC/ Abboud CN, see DiPersio JF immunoglobulin Heavy-Chain Fusion Gene, 510 Abbruzzese JL, see Hoff PM Alba E, see Pérez-Manga G —see Pisters PWT Albain KS, see Hillner BE Abdolell M, see Brezden CB Albanell J, see Bellmunt J Abeloff M, see Sledge GW Jr Albers P, see von der Maase H Abgrall JF, see Harousseau JL Alberto P, see Hiigli A Abhyankar SH, see Godder KT Alberts DS, see Monsky WL Abner A, see Park CC —see Peters WA III Abonour R, see Bhatia S Alberts SR, see Adjei AA Abraksia S, Kumar PD, Kasal J. Two Unusual Lymphomas; Case |: Albright L, see Thomas PRM Primary Malignant Lymphoma (Diffuse Large B-Cell Lym- Aldrighetti D, see Boccardo F phoma) of the Spleen Mimicking Splenic Abscess, 3731 Aleksandrovic J, see Jeremic B Abrams J, see Krag D Aleman BMP, see van Leeuwen FE Abrey LE, Yahalom J, DeAngelis LM. Treatment for Primary CNS Alexandre J, Bleuzen P, Bonneterre J, Sutherland W, Misset JL, Lymphoma: The Next Step, 3144 Guastalla J-P, Viens P, Faivre S, Chahine A, Spielman M, Ackermann J, see K6nigsberg R Bensmaine A, Marty M, Mahjoubi M, Cvitkovic E. Factors Acute Lymphoblastic Leukemia Committee of the Tokyo Children’s Predicting for Efficacy and Safety of Docetaxel in a Com- Cancer Study Group, see Toyoda Y passionate-Use Cohort of 825 Heavily Pretreated Advanced Adam R, see Giacchetti S Breast Cancer Patients, 562 Adams K, see Apostolidis J Alexanian R, Anderson K, Barlogie B, Berenson J, Dalton WS, Kyle Adams R, see Grupp SA RA. In Memoriam: Syndney E. Salmon, M.D., 1 Adamson PC, see Warren KE Allegra CJ, see Takimoto CH Adelstein DJ, Rice TW, Rybicki LA, Larto MA, Ciezki J, Saxton J, Allen JC, see Thomas PRM DeCamp M, Vargo JJ, Dumot JA, Zuccaro G. Does Pacli- Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, taxel Improve the Chemoradiotherapy of Locoregionally Heiss MM. c-ErbB-2 Is of Independent Prognostic Relevance Advanced Esophageal Cancer? A Nonrandomized Compari- in Gastric Cancer and Is Associated With the Expression of son With Fluorouracil-Based Therapy, 2032 Tumor-Associated Protease Systems, 2201 Adi S, see Idelevich E Allman D, see Van Cutsem E Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Allred DC, see Zellars RC Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J. Almadrones L, see Barakat RR Phase I and Pharmacologic Study of Sequences of Gemcit- Alquati P, see Berruti A abine and the Multitargeted Antifolate Agent in Patients With Alvarez R, see Muggia FM Advanced Solid Tumors, 1748 Alvarez RD, see Muggia FM Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot Al-Zoubi A, see Savarese D HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Amabile M, see Martinelli G Erlichman C. Phase I and Pharmacokinetic Study of Irinote- Amadori D, Nanni O, Marangolo M, Pacini P, Ravaioli A, Rossi A, can and Docetaxel in Patients With Advanced Solid Tumors: Gambi A, Catalano G, Perroni D, Scarpi E, Giunchi DC, Preliminary Evidence of Clirical Activity, 1116 Tienghi A, Becciolini A, Volpi A. Disease-Free Survival Agarwala S, see Hillner BE Advantage of Adjuvant Cyclophosphamide, Methotrexate, Agostini P, see Cuneo A and Fluorouracil in Patients With Node-Negative, Rapidly A’Hern R, see Spillane AJ Proliferating Breast Cancer: A Randomized Multicenter Ahrens S, see Cotterill SJ Study, 3125 Ah-See AK, see Smith IC Amato R, see Stadler WM Ahtola H, see Salovaara R Amdur RJ, see Mendenhall WM Aida N, see Nishihira H American Society of Clinical Oncology, see Desch CE Aikin AA, see Warren KE American Society of Clinical Oncology Bisphosphonates Expert Panel, Aisenberg AC, Finkelstein DM. Second Malignancies in Hodgkin’s see Hillner BE Disease (correspondence), 2185 American Society of Clinical Oncology Growth Factors Expert Panel, Aisner J, see Kamen BA see Ozer H see Kaufman D Ames FC, see Breslin TM Ajani JA. Standard Chemotherapy for Gastric Carcinoma: Is It a Myth? Amess JAL, see Apostolidis J (correspondence), 4001 —see Micallef INM Akabani G, see Cokgor I Ammassari A, see Cingolani A 4ii2 Journal of Clinical Oncology, Vol 18, No 24 (December 15), 2000: pp 4112-4164 AUTHOR INDEX Aalders JG, see de Hullu JA Akard L. Optimum Methods to Mobilize Stem Cells (correspondence), Aaltonen LA, see Salovaara R 3063 Aamdal S, see Middleton MR Akard LP, see Fife BL Aaron D, see Boon H Akasaka H, see Akasaka T Aaronson N, see Middleton MR Akasaka T, Akasaka H, Ueda C, Yonetani N, Maesako Y, Shimizu A, Aaronson NK, see Detmar SB Yamabe H, Fukuhara S, Uchiyama T, Ohno H. Molecular —see Lonning PE and Clinical Features of Non-Burkitt’s, Diffuse Large-Cell Abbasciano V, see Sartori S Lymphoma of B-Cell Type Associated with the c-MYC/ Abboud CN, see DiPersio JF immunoglobulin Heavy-Chain Fusion Gene, 510 Abbruzzese JL, see Hoff PM Alba E, see Pérez-Manga G —see Pisters PWT Albain KS, see Hillner BE Abdolell M, see Brezden CB Albanell J, see Bellmunt J Abeloff M, see Sledge GW Jr Albers P, see von der Maase H Abgrall JF, see Harousseau JL Alberto P, see Hiigli A Abhyankar SH, see Godder KT Alberts DS, see Monsky WL Abner A, see Park CC —see Peters WA III Abonour R, see Bhatia S Alberts SR, see Adjei AA Abraksia S, Kumar PD, Kasal J. Two Unusual Lymphomas; Case |: Albright L, see Thomas PRM Primary Malignant Lymphoma (Diffuse Large B-Cell Lym- Aldrighetti D, see Boccardo F phoma) of the Spleen Mimicking Splenic Abscess, 3731 Aleksandrovic J, see Jeremic B Abrams J, see Krag D Aleman BMP, see van Leeuwen FE Abrey LE, Yahalom J, DeAngelis LM. Treatment for Primary CNS Alexandre J, Bleuzen P, Bonneterre J, Sutherland W, Misset JL, Lymphoma: The Next Step, 3144 Guastalla J-P, Viens P, Faivre S, Chahine A, Spielman M, Ackermann J, see K6nigsberg R Bensmaine A, Marty M, Mahjoubi M, Cvitkovic E. Factors Acute Lymphoblastic Leukemia Committee of the Tokyo Children’s Predicting for Efficacy and Safety of Docetaxel in a Com- Cancer Study Group, see Toyoda Y passionate-Use Cohort of 825 Heavily Pretreated Advanced Adam R, see Giacchetti S Breast Cancer Patients, 562 Adams K, see Apostolidis J Alexanian R, Anderson K, Barlogie B, Berenson J, Dalton WS, Kyle Adams R, see Grupp SA RA. In Memoriam: Syndney E. Salmon, M.D., 1 Adamson PC, see Warren KE Allegra CJ, see Takimoto CH Adelstein DJ, Rice TW, Rybicki LA, Larto MA, Ciezki J, Saxton J, Allen JC, see Thomas PRM DeCamp M, Vargo JJ, Dumot JA, Zuccaro G. Does Pacli- Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, taxel Improve the Chemoradiotherapy of Locoregionally Heiss MM. c-ErbB-2 Is of Independent Prognostic Relevance Advanced Esophageal Cancer? A Nonrandomized Compari- in Gastric Cancer and Is Associated With the Expression of son With Fluorouracil-Based Therapy, 2032 Tumor-Associated Protease Systems, 2201 Adi S, see Idelevich E Allman D, see Van Cutsem E Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Allred DC, see Zellars RC Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J. Almadrones L, see Barakat RR Phase I and Pharmacologic Study of Sequences of Gemcit- Alquati P, see Berruti A abine and the Multitargeted Antifolate Agent in Patients With Alvarez R, see Muggia FM Advanced Solid Tumors, 1748 Alvarez RD, see Muggia FM Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot Al-Zoubi A, see Savarese D HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Amabile M, see Martinelli G Erlichman C. Phase I and Pharmacokinetic Study of Irinote- Amadori D, Nanni O, Marangolo M, Pacini P, Ravaioli A, Rossi A, can and Docetaxel in Patients With Advanced Solid Tumors: Gambi A, Catalano G, Perroni D, Scarpi E, Giunchi DC, Preliminary Evidence of Clirical Activity, 1116 Tienghi A, Becciolini A, Volpi A. Disease-Free Survival Agarwala S, see Hillner BE Advantage of Adjuvant Cyclophosphamide, Methotrexate, Agostini P, see Cuneo A and Fluorouracil in Patients With Node-Negative, Rapidly A’Hern R, see Spillane AJ Proliferating Breast Cancer: A Randomized Multicenter Ahrens S, see Cotterill SJ Study, 3125 Ah-See AK, see Smith IC Amato R, see Stadler WM Ahtola H, see Salovaara R Amdur RJ, see Mendenhall WM Aida N, see Nishihira H American Society of Clinical Oncology, see Desch CE Aikin AA, see Warren KE American Society of Clinical Oncology Bisphosphonates Expert Panel, Aisenberg AC, Finkelstein DM. Second Malignancies in Hodgkin’s see Hillner BE Disease (correspondence), 2185 American Society of Clinical Oncology Growth Factors Expert Panel, Aisner J, see Kamen BA see Ozer H see Kaufman D Ames FC, see Breslin TM Ajani JA. Standard Chemotherapy for Gastric Carcinoma: Is It a Myth? Amess JAL, see Apostolidis J (correspondence), 4001 —see Micallef INM Akabani G, see Cokgor I Ammassari A, see Cingolani A 4ii2 Journal of Clinical Oncology, Vol 18, No 24 (December 15), 2000: pp 4112-4164 AUTHOR INDEX Amoroso D, see Boccardo F Athow A, see Mokbel K Amos CI, see Frazier ML Atkins M, see Manola J Ancelot M, see Le Gouill S Atkinson EN, see Verschraegen CF Anderson JR, see Baker KS Atkinson JB, see Nickerson HJ Anderson K, see Alexanian R; Crémieux P-Y see Perez CA Anderson SA, see Smalley RV Attal M, see Blaise D Anderson V, see Baselga J Attar EC, Ervin T, Janicek M, Deykin A, Godleski J. Acute Interstitial Andersson M, see Metayer C Pneumonitis Related to Gemcitabine, 693 Andreeff M, see Kantarjian HM Auclere MF, see Michel G Andreesen R, see Blank C Audhuy B, see Harousseau JL Andre F, Grunenwald D, Pignon J-P, Dujon A, Pujol JL, Brichon PY, Auvrignon A, see Michel G Brouchet L, Quoix E, Westeel V, Le Chevalier T. Survival of Au WY, see Liang R Patients With Resected N2 Non—Small-Cell Lung Cancer: Au WY, Ma SK, Ooi C, Liang R, Kwong YL. Unusual Manifestations Evidence for a Subclassification and Implications, 2981 of Acute Leukemia; Case 1: CNS Extramedullary Relapse of Andre M, see Wijermans P Acute Promyelocytic Leukemia After Arsenic Trioxide- Andrulis IL, see Wunder JS Induced Remission, 3435 Aneliunas V, see Wunder JS Au WY, Shek TW, Ma SK, Leung G, Ooi GC, Liang R, Kwong YL. Angelberger P, see Raderer M Myeloblastoma (Chloroma) in Leukemia; Case 2: Meningeal Angiolini C, see Venturini M Granulocytic Sarcoma (Chloroma) in Essential Thrombocy- Annunziata M, see Ferrara F themia, 3996 Ansquer Y, see Stoppa-Lyonnet D Avet-Loiseau H, see Le Gouill S Antin JH, see Lee SJ Avril N, see Schelling M Antinori A, see Cingolani A Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Antolak JA, see Pollack A Ziegler S, Graeff H, Schwaiger M. Breast Imaging With Antonescu CR, see Lewis JJ Positron Emission Tomography and Fluorine-18 Fluorode- Apostolidis J, see Micallef INM oxyglucose: Use and Limitations, 3495 Apostolidis J, Gupta RK, Grenzelias D, Johnson PWM, Pappa VI, Awada A, see Paridaens R Summers KE, Salam A, Adams K, Norton AJ, Amess JAL, Axtell RA, see Henrickson KJ Matthews J, Bradburn M, Lister TA, Rohatiner AZS. High- Aylesworth C, see Rowinsky EK Dose Therapy With Autologous Bone Marrow Support as Ayoub J, see von Pawel J Consolidation of Remission in Follicular Lymphoma: Long- Azli N, see Fandi A Term Clinical and Molecular Follow-Up, 527 Arbuck SG, see Takimoto CH Babic R, see Allgayer H Arceci RJ, see Dahl GV Bacchini P, see Bacci G Arcediano A, see Gomez-Martin C Bacci G, Ferrari S, Bertoni F, Donati D, Bacchini P, Longhi A, del Arcenas A, see von Pawel J Prever AB, Forni C, Rimondini S. Neoadjuvant Chemother- Arends JW, see van Oostenbrugge RJ apy for Peripheral Malignant Neuroectodermal Tumor of Arico M, see Caselli D Bone: Recent Experience at the Istituto Rizzoli, 885 Arimidex Study Group, see Bonneterre J Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, —see Nabholtz JM Forni C, Manfrini M, Donati D, Picci P. Prognostic Factors in Arkhipov A, see Kaufmann M Nonmetastatic Ewing’s Sarcoma of Bone Treated With —see Lgnning PE Adjuvant Chemotherapy: Analysis of 359 Patients at the Arlen P, see Marshall JL Istituto Ortopedico Rizzoli, 4 Armand J-P, see Boige V Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei see Couteau C R, Fabbri N, Forni C, Versari M, Campanacci M. Long-Term —see Fandi A Outcome for Patients With Nonmetastatic Osteosarcoma of —see Fizazi K the Extremity Treated at the Instituto Ortopedico Rizzoli Armitage JO. Myelodysplasia and Acute Leukemia After Autologous According to the Instituto Ortopedico Rizzoli/Osteosarco- Bone Marrow Transplantation (editorial), 945 ma-2 Protocol: An Updated Report, 4016 Armitage JO, see Bishop MR Bachouchi M, see Fandi A —see Ozer H Bacik J, see Motzer RJ Arndt CAS, see Cagnoni PJ Badell I, see Marco F Aronin P, see Thomas PRM Baekelandt M, Holm R, Nesland JM, Tropé CG, Kristensen GB. Asbell S, see Valicenti R Expression of Apoptosis-Related Proteins Is an Independent Ascani S, see Zinzani PL Determinant of Patient Prognosis in Advanced Ovarian Ashley DM, see Friedman HS Cancer, 3775 Ashley R, see Potters L Bafaloukos D, see Briasoulis E Asselain B, see Delozier T Baggen MGA, see Bontenbal M —see Stoppa-Lyonnet D Baggers J, Ratzinger G, Young JW. Dendritic Cells as Immunologic Aster JC, see Hecht JL Adjuvants for the Treatment of Cancer (editorial), 3879 Atherton P, see Adjei AA Bahary JP, see Del Rowe J 4114 AUTHOR INDEX Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Tumor and Advanced Neuroblastoma: A Cross-Sectional Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Study, 3280 Johnson MD, Hawkins MJ, Lippman ME, Hayes DF. Phase Barrett B, see Crémieux P-Y II Evaluation of Thalidomide in Patients With Metastatic Barrett RJ II, see Peters WA III Breast Cancer, 2710 Bartlett NL, see Horning SJ Bailes J. Managed Care Oncology: The Quality Debate (editorial), 705 Barton CM, see Smith IE Bailes JS. Presidential Address, 2s Barton DL, see Loprinzi CL Bailey S, see Mann JR see Quella SK Bains M, see Motzer RJ see Sloan JA Bajetta E, see Kaufmann M Barton M, see O’Brien P see Lgnning PE Baruchel A, see Michel G Bajorin D, see Motzer RJ —see Morschhauser F Bajorin DF, see Dodd PM Baselga J, see Bellmunt J —see Motzer RJ Baselga J. New Therapeutic Agents Targeting the Epidermal Growth Baker CS, see Earle CC Factor Receptor, 54s Baker KS, Anderson JR, Link MP, Grier HE, Qualman SJ, Maurer HM, Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, Breneman JC, Wiener ES, Crist WM. Benefit of Intensified D’ Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Therapy for Patients With Local or Regional Embryonal Anderson V, Waksal H, Mendelsohn J. Phase I Studies of Rhabdomyosarcoma: Results From the Intergroup Rhabdo- Anti-Epidermal Growth Factor Receptor Chimeric Antibody myosarcoma Study IV, 2427 C225 Alone and in Combination With Cisplatin, 904 Baker SD, Diasio RB, O’Reilly S, Lucas VS, Khor SP, Sartorius SE, Bash RO, see Mantadakis E Donehower RC, Grochow LB, Spector T, Hohnecker JA, Basili LA, see Dorval M Rowinsky EK. Phase I and Pharmacologic Study of Oral Basser RL, Underhill C, Davis I, Green MD, Cebon J, Zalcberg J, Fluorouracil on a Chronic Daily Schedule in Combination MacMillan J, Cohen B, Marty J, Fox RM, Begley CG. With the Dihydropyrimidine Dehydrogenase Inactivator Eni- Enhancement of Platelet Recovery After Myelosuppressive luracil, 915 Chemotherapy by Recombinant Human Megakaryocyte Baker SD, see Eckhardt SG Growth and Development Factor in Patients With Advanced —see Gallo JM Cancer, 2852 Balcerzak SP, see Fisher RI Bastert G, see Sauerbrei W Balducci L, see Extermann M see Schmoor C Balis FM, see Warren KE Basttis R, see Bellmunt J Baliva G, see Zinzani PL Batiste-Alentorn E, see Bellmunt J Balmer A, see Beck MN Battista R, see Zinzani PL Band RA, see Takimoto CH Bauduer F, see Michel G Bandarenko N, see Sood N Bauer KA. Venous Thromboembolism in Malignancy (editorial), 3065 Bandini G, see Martinelli G Baum CM, see DiPersio JF Banks PM, see Socié G Baume D, see Girinsky T Bants JM, see Bellmunt J Beale P, see Briasoulis E Barakat RR, Gilewski TA, Almadrones L, Saigo PE, Venkatraman E, Bearman SI, see Nieto Y Hudis C, Hoskins WJ. Effect of Adjuvant Tamoxifen on the Beauchamp CP, see Wunder JS Endometrium in Women With Breast Cancer: A Prospective Beauchamp RD, see Talamonti MS Study Using Office Endometrial Biopsy, 3459 Beaudre A, see Girinsky T Barakat RR. In Reply (correspondence), 445 Beaune P, see Cabelguenne A Baral RN, see Foon KA Becciolini A, see Amadori D Barber JA, see Swerdiow AJ Beck MN, Balmer A, Dessing C, Pica A, Munier F. First-Line Barbieri RL, see Holmes MD Chemotherapy With Local Treatment Can Prevent External- Barcos M, see Berry DA Beam Irradiation and Enucleation in Low-Stage Intraocular Barcos MP, see Green DM Retinoblastoma, 2881 Bardi A, see Cuneo A Beck T, see Mani S Barista I. Intrathecal Cytarabine and Bone Marrow Suppression (cor- Beckwith C, Butera J, Sadaniantz A, King TC, Fingleton J, Rosmarin respondence), 2003 AG. Non-Hodgkin’s Lymphoma Involving the Heart; Case 1: Barlogie B, see Alexanian R Primary Transmural Cardiac Lymphoma, 1996 Barnes EA, Hanson J, Neumann CM, Nekolaichuk CL, Bruera E. Bégin LR, see Chappuis PO Communication Between Primary Care Physicians and Ra- Begley CG, see Basser RL diation Oncologists Regarding Patients With Cancer Treated Behm F, see Sandlund JT With Palliative Radiotherapy, 2902 Behn M, see Kersting M Baron B, see Vanhoefer U Beijnen JH, see Malingré MM —see Wilke H Beitler J. Why Stop at Using High-Dose-Rate Brachytherapy as a Boost Baron RA, see Boon H for the Prostate? (correspondence), 4003 Barr RD, Chalmers D, De Pauw S, Furlong W, Weitzman S, Feeny D. Belani C, see Gandara DR Health-Related Quality of Life in Survivors of Wilms’ Belin TR, see Bower JE AUTHOR INDEX Belinson J, see Markman M Bermtidez J, see Cafiete A Belkora JK, see Sepucha KR Bernard JL, see Frappaz D Bell CM, see Earle CC Bernard SA, Bruera E. Drug Interactions in Palliative Care, 1780 Bell RS, see Wunder JS Bernaudin J-F, see Temam S Bell WN, see Mani S Bernhard J, see Coates AS Belli M, see Frasci G —see Crivellari D Bellmunt J, Guillem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Bernhardt B. Correspondence Re: ‘Doc, Shouldn’t We Be Getting Batiste-Alentorn E, Saenz A, Lopez-Brea M, Font A, Nogué Some tests?* (correspondence), 3739 M, Basttis R, Climent MA, de la Cruz JJ, Albanell J, Banus Bernhardt BA, see Matloff ET JM, Gallardo E, Diaz-Rubio E, Cortés-Funes H, BaselgaJ for Bernini G, see Faulkner LB the Spanish Oncology Genitourinary Group. Phase I-II Study Berns EMJJ, see Verhoog LC of Paclitaxel, Cisplatin, and Gemcitabine in Advanced Tran- Bernstein M, see Estlin EJ sitional-Cell Carcinoma of the Urothelium, 3247 Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, Belly RT, see Zujewski J Botta M, Tampellini M, Donadio “M, Mancarella S, De Lena Ben-Baruch N, see Idelevich E M, Alquati P, Dogliotti L. Phase II Study of Vinorelbine Bendandi M, see Zinzani PL With Protracted Fluorouracil Infusion as a Second- or Third- Benedetti-Panici P, see Piccart MJ Line Approach for Advanced Breast Cancer Patients Previ- Benhamou E, see Girinsky T ously Treated With Anthracyclines, 3370 Benjamin RS, see Meric F Berry D, see Blackwell K see Pisters PWT Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Benner S, see Hoff PM Budman DR, Henderson IC, Barcos M, Hayes D, Norton L. Bennett CL, see Ozer H HER-2/neu and p53 Expression Versus Tamoxifen Resis- Bennett CL, Stinson TJ, Vogel V, Robertson L, Leedy D, O’Brien P, tance in Estrogen Receptor—Positive, Node-Positive Breast Hobbs J, Sutton T, Ruckdeschel JC, Chirikos TN, Weiner Cancer, 3471 RS, Ramsey MM, Wicha MS. Evaluating the Financial Bertelli G, see Venturini M Impact of Clinical Trials in Oncology: Results From a Pilot Bertheaut-Cvitkovic F, see Giacchetti S Study From the Association of American Cancer Institutes/ Berthold F, see Poremba C Northwestern University Clinical Trials Costs and Charges Berthou C, see Michel G Project, 2805 Berthou P, see Morschhauser F Bennett JM, see Hochster HS Bertoni F, see Bacci G —see Horning SJ Bertrand Y, see Landman-Parker J Bennett K, see Norris B Besenval M, see Gelmon KA Benoehr C, see Santoro A Bessell EM, see Foran JM Bense S, see Avril N Bessho F, see Toyoda Y Bensmaine A, see Alexandre J Betaille R, see Le Gouill S Benson AB III, see Desch CE Betman L, see Israel O see Harris JE Beudeker M, see Bontenbal M —see Talamonti MS Beveridge RA, Regan DH. Evaluation: Continued Need for Random- Bentzen SM, see Rustin GJS ized Trials (correspondence), 3321 Benz CC, see Thor AD Beyerle C, see Sauerbrei W Benzohra A, see Foran JM Bezjak A, see Geels P Beran M, see Kantarjian HM —see Kirkbride P Berard CW, see Sandlund JT Bhatia S, see Porcu P Berd D, see Ejadi S Bhatia S, Abonour R, Porcu P, Seshadri R, Nichols CR, Cornetta K, Berdel WE, see Koch P Einhorn LH. High-Dose Chemotherapy as Initial Salvage Berek JS, see Peters WA III Chemotherapy in Patients With Relapsed Testicular Cancer, Berenson J, see Alexanian R 3346 Berenson JR, see Hillner BE Bhattacharya-Chatterjee M, see Foon KA Berg C, see Pierce LJ Bi D-Q, see Grem JL Berg WJ, see Motzer RJ Bianco A, see Frasci G Berger C, see Frappaz D Biegel JA, see Grotzer MA Berger NA, see Takimoto CH Bienvenu J, see Voog E Berger SJ, see Takimoto CH Biermann JS, see Hillner BE Bergman B, see von Pawel J Biganzoli E, see Coradini D Bergstralh EJ, see Cheng L Biganzoli L, see Paridaens R Bergstrom K, see Swanson G Bigner DD, see Cokgor I Berille J, see Shepherd FA see Friedman HS Berkey BA, see Coia LR Bigner SH, see Cokgor I Berkowitz RS, see Lu KH Bigoni R, see Cuneo A Berlin J, see Talamonti MS Bilancia D, see Comella P Berman S, see Feld R see Frasci G 4116 AUTHOR INDEX Billingham L, Cullen M. In Reply (correspondence), 1800 Bogaerts J, see Gatzemeier U Birch R, see Weaver CH Boige V, Raymond E, Faivre S, Gatineau M, Meely K, Mekhaldi S, Biron P, see Blay J-Y Pautier P, Ducreux M, Rixe O, Armand J-P. Phase I and —see Tilly H Pharmacokinetic Study of the Camptothecin Analog DX- Bishop MC, see Hughes ODM 8951f Administered as a 30-Minute Infusion Every 3 Weeks Bishop MR, Tarantolo SR, Pavletic ZS, Lynch JC, Morris ME, in Patients With Advanced Cancer, 3986 Zacharias D, Armitage JO, Kessinger A. Filgrastim as an Boiron J-M, see Blaise D Alternative to Donor Leukocyte Infusion for Relapse After Bojar H, see Sauerbrei W Allogeneic Atem-Cell Transplantation, 2269 Bok R, see Small EJ Bjurstrom T, see Johnston E Bol CJ, see Zujewski J Black JL, see Warren KE Bolis G, see Lavarino C Black PM, see Fine HA Bolla M, see Hiigli A Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, Bollinger JW, see Martenson JA Dewhirst M, Greenberg C. Plasma D-Dimer Levels in Oper- Bolognesi A, see Boccardo F able Breast Cancer Patients Correlate With Clinical Stage Bolwell B, see Davies SM and Axillary Lymph Node Status, 600 Bonadonna G, see Santoro A Blackwell S, see Johnston E Bond SJ, see Rustin GJS Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, Bonetti A, see de Gramont A Jouet J-P, Attal M, Bordigoni P, Cahn J-Y, Boiron J-M, —see Piccart MJ Schuller M-P, Moatti J-P, Michallet M. Randomized Trial of Bonetti M, see Colleoni M Bone Marrow Versus Lenograstim-Primed Blood Cell Allo- —see Crivellari D geneic Transplantation in Patients With Early-Stage Leuke- Bonfante V, see Santoro A mia: A Report From the Société Frangaise de Greffe de Boni C, see de Gramont A Moelle, 537 Bonithon-Kopp C, see Chaplain G Blanco G, see Holli K Bonnay M, see Fizazi K Blank C, Wagner HM, Hohenleutner U, Andreesen R. Unusual Bonnefoi H, see Hiigli A Manifestations of Acute Leukemia; Case 2: Leukemia and Bonner JA, Raisch KP, Trummell HQ, Robert F, Meredith RF, Spencer Rash: Paraneoplastic or Drug-Induced?, 3437 SA, Buchsbaum DJ, Saleh MN, Stackhouse MA, LoBuglio Blay JY, see Le Cesne A AF, Peters GE, Carroll WR, Waksal HW. Enhanced Apopto- Blay J-Y, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P. sis With Combination C225/Radiation Treatment Serves as High-Dose Chemotherapy With Autologous Hematopoietic the Impetus for Clinical Investigation in Head and Neck Stem-Cell Transplantation for Advanced Soft Tissue Sar- Cancers, 47s coma in Adults, 3643 Bonneterre J, see Alexandre J Bleiberg H, see Vanhoefer U Bonneterre J, Thiirlimann B, Robertson JFR, Krzakowski M, Mauriac Blessing JA, see McGuire WP L, Koralewski P, Vergote I, Webster A, Steinberg M, von Bleuzen P, see Alexandre J Euler M for the Arimidex Study Group. Anastrozole Versus Blitzer JB, see Nagourney RA Tamoxifen as First-Line Therapy for Advanced Breast Can- Blobe GC, Mantel M, Janicek M, Demetri GD. Uterine Sarcoma, 2341 cer in 668 Postmenopausal Women: Results of the Tamox- Blodd P, see Kirkbride P ifen or Arimidex Randomized Group Efficacy and Tolerabil- Blons H, see Cabelguenne A ity Study, 3748 Bloomfield CA, see Harris NL Bonomi P, see Gandara DR Blum RH, see Kirkwood JM Bonomi P, Kim KM, Fairclough D, Cella D, Kugler J, Rowinsky E, Blumberg D, see Lewis JJ Jiroutek M, Johnson D. Comparison of Survival and Quality Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi of Life in Advanced Non—Small-Cell Lung Cancer Patients P, Giai M, Genta F, Pacini P, Distante V, Bolognesi A, Treated With Two Dose Levels of Paclitaxel Combined With Aldrighetti D, Farris A, and Other Participants in the Italian Cisplatin Versus Etoposide With Cisplatin: Results of an Breast Cancer Adjuvant Study Group. Cyclophosphamide, Eastern Cooperative Oncology Group Trial, 623 Methotrexate, and Fluorouracil Versus Tamoxifen Plus Bontenbal M, van Putten WLJ, Burghouts JThM, Baggen MGA, Ras Ovarian Suppression as Adjuvant Treatment of Estrogen GJ, Stiegelis WF, Beudeker M, Janssen JThP, Braun JJ, van Receptor—Positive Pre-/Perimenopausal Breast Cancer Pa- der Linden GHM, van der Velden PC, van Geel AN, Helle P, tients: Results of the Italian Breast Cancer Adjuvant Study Leisink M, Foekens JA, Klijn JGM. Value of Estrogenic Group 02 Randomized Trial, 2718 Recruitment Before Chemotherapy: First Randomized Trial Boccardo F (on Behalf of the Italian Prostate Cancer Project). In Reply in Primary Breast Cancer, 734 (correspondence), 445 Bookman MA, see McGuire WP Boccuni P, see Ferrara F Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, Boddy AV, see Thomas H MeWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka Bodenstein H, see Vanhoefer U T. Use of Complementary/Alternative Medicine by Breast Bodensteiner D, see Cagnoni PJ Cancer Survivors in Ontario: Prevalence and Perceptions, Bodey G, see Elting LS 2515 Bodrogi I, see von der Maase H Boracchi P, see Coradini D Boecker W, see Poremba C Bordessoule D, see Tilly H AUTHOR INDEX 4117 Bordigoni P, see Blaise D Sentinel Lymph Node Biopsy Is Accurate After Neoadjuvant —see Michel G Chemotherapy for Breast Cancer, 3480 Borell TJ, see Smith JS Breslow N, see Porteus MH Borgomastro A, see Zampa G Bretscher M. Caring for Dying Patients: What Is Right?, 233 Bormans G, see Flamen P Brewer H, see Saleh MN Bos M, see Baselga J Brezden CB, Phillips K-A, Abdolell M, Bunston T, Tannock IF. Bosl GJ, see Motzer RJ Cognitive Function in Breast Cancer Patients Receiving Bosly A, see Haioun C Adjuvant Chemotherapy, 2695 —see Tilly H Briasoulis E, Judson I, Pavlidis N, Beale P, Wanders J, Groot Y, —see Wijermans Veerman G, Schuessler M, Niebch G, Siamopoulos K, Bostrom BC, see Heerema NA Tzamakou E, Rammou D, Wolf L, Walker R, Hanauske A. Bostwick DG, see Cheng L Phase I[ Trial of 6-Hour Infusion of Glufosfamide, a New Bot FJ, see Veltman JA Alkylating Agent With Potentially Enhanced Selectivity for Botta M, see Berruti A Tumors That Overexpress Transmembrane Glucose Trans- Bottini A, see Berruti A porters: A Study of the European Organization for Research Bouaouina N, see Girinsky T and Treatment of Cancer Early Clinical Studies Group, Boucher J, see Savarese D Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Bouffet E, see Frappaz D Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis Bouhour D, see Blay J-Y N. Carboplatin Plus Paclitaxel in Unknown Primary Carci- Bourhis JH, see Blaise D noma: A Phase II Hellenic Cooperative Oncology Group Bourhis J-H, see Girinsky T Study, 3101 Bourquelot P, see Mamzer-Bruneel M-F Brice P, see Haioun C Bourstyn E, see Stoppa-Lyonnet D Brichon PY, see Andre F Bouscary M-L, see Macquart-Moulin G Bridges KD, see Godder KT Boussen H, see Fandi A Bridier A, see Girinsky T Bowden C, see Zujewski J Briere J, see Guermazi A Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Briére J, see Haioun C Belin TR. Fatigue in Breast Cancer Survivors: Occurrence, —see Tilly H Correlates, and Impact on Quality of Life, 743 Brierley K, see Matloff ET Bowman L, see Phipps S Brignoli S, see Pestalozzi BC Bowman LC, see Leung W Briot E, see Girinsky T Boyd JH, see Lowe VJ British Medical Research Council Lung Cancer Working Party, see Boyer M, see Klastersky J Hopwood P —see von Pawel J Britten CD, see Eckhardt SG Boyett JM, see Thomas PRM Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Boyle MG, see Dodd PM Eschwege F, Zhang J, Russell L, Oster W, Sauer R. Phase III Brabbins DS, see Kestin LL Randomized Trial of Amifostine as a Radioprotector in Head Brada M, see Osoba D and Neck Cancer, 3339 Bradburn M, see Apostolidis J Broadwater G, see Berry DA Brady MF, see Muggia FM —see Blackwell K Brainstem Glioma Cooperative Group, see Broniscer A Brock P, see Pritchard J Braly PS, see Muggia FM Brockstein BE. Reduction of Distant Metastases in Head and Neck Brasnu D, see Cabelguenne A Cancer With Concomitant Chemotherapy (correspondence), Braun JJ, see Bontenbal M 3320 Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Brodeur GM, see Maris JM Sommer H, Pantel K. Lack of Effect of Adjuvant Chemo- —see Nickerson HJ therapy on the Elimination of Single Dormant Tumor Cells in —see Schmidt ML Bone Marrow of High-Risk Breast Cancer Patients, 80 Bromberg JI, see Dorval M Bredenfeld H, see Santoro A Broniscer A, da Costa Leite C, Lanchote VL, Machado TMS, Crist6- Brekelmans CTM, see Verhoog LC fani LM, and the Brainstem Glioma Cooperative Group. Brendel C, see Schmidt M Radiation Therapy and High-Dose Tamoxifen in the Treat- Breneman JC, see Baker KS ment of Patients With Diffuse Brainstem Gliomas: Results of Brennan MB, see Giuliano AE a Brazilian Cooperative Study, 1246 Brennan MF, see Lewis JJ Brooks SE, see Zamboni WC see Linehan DC Brophy N, see Dahl GV Brenner B, see Idelevich E Brouchet L, see Andre F Bresciani G, see Coradini D Broun ER, see Fife BL see Lavarino C Brousse N, see Mamzer-Bruneel M-F Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, Brouwer E, see de Jonge MJA Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Brown CM, see McMasters KM Singletary SE, Buzdar AU, Hortobagyi GN, Hunt KK. Brown F, see Janne PA 4118 AUTHOR INDEX Brown J, see Pritchard J Byrd J, see Venook AP Brown JB, see Boon H Brown R, see Mackay HJ Cabanillas F. Interferon Does Not Prolong Progression-Free Survival Bruera E, MacDonald N. To Hydrate or Not to Hydrate: How Should After ProMACE-MOPP (correspondence), 3322 It Be?, 1156 Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier A-M, Soussi Bruera E, see Barnes EA T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P. p53 —see Bernard SA Alterations Predict Tumor Response to Neoadjuvant Chemo- Brunelli A, see Berruti A therapy in Head and Neck Squamous Cell Carcinoma: A Brunet J-S, see Chappuis PO Prospective Series, 1465 Brunetti C, see Lorusso V Cabriales S, see Tulpule A Bruning P, see Paridaens R Cady B. Sentinel Lymph Node Procedure in $quamous Cell Carcinoma Bruno R, see Couteau C of the Vulva (editorial), 2795 Bubley G, see Shaneyfelt T Cagnoni PJ, see Nieto Y Buchholz TA, see Katz A Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Buchsbaum DJ, see Bonner JA Greenberg RN, Arndt CAS, Schuster M, Seibel N, Yeldandi Buckley JD, see Gamis AS V, Tong KB. Pharmacoeconomic Analysis of Liposomal Buckner CD, see Weaver CH Amphotericin B Versus Conventional Amphotericin B in the Buclon M, see Frappaz D Empirical Treatment of Persistently Febrile Neutropenic Budman D, see Venook AP Patients, 2476 Budman DR, see Berry DA Cagossi K, see Federico M Bueno R, see Sekeres M —see Sabbatini R Buesa J, see Verweij J Cahn J-Y, see Blaise D Buhl P, see Langer SW —see Davies SM Bull SB, see Wunder JS Caillot D, see Yakoub-Agha I Biiller HR, see Hutten BA Cairo MS, see Gururangan S Bunin GR, see Friedman DL —see Lones MA Bunin N, see Grupp SA Calaminus G, see Schneider DT Bunnell CA, see Burstein HJ Callard P, see Temam S Bunston T, see Brezden CB Calzone K, see Dorval M Bureo E, see Marco F Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA, Burger HU, see Van Cutsem E Ellison R, Warrell RP Jr. Leukocytosis and the Retinoic Acid Burger PC, see Smith JS Syndrome in Patients With Acute Promyelocytic Leukemia Burgers JMV, see van Leeuwen FE Treated With Arsenic Trioxide, 2620 Burgess MA, see Meric F Cameron D, see Mackay HJ Burghouts JThM, see Bontenbal M Camitta B, see Mahoney DH Jr Burkes R, see Shepherd FA Camitta BM, see Davies SM Burnett CB, see Cheng JD see Pollock BH Burns P, see Madajewicz S Campanacci M, see Bacci G Burstein HJ. Discussing Complementary Therapies With Cancer Pa- Campbell E, see Hidalgo M tients: What Should We Be Talking? (editorial), 2501 Canellos GP, see Loprinzi CL Burstein HJ. Radiation Recall Dermatitis from Gemcitabine, 693 Canellos GP. Introduction, Is Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Canellos GP. The Policing of Clinical Trials (editorial), 2353 Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer Cafete A, Castel V, Navarro S. In Reply (correspondence), 2788 EP. Docetaxel Administered on a Weekly Basis for Meta- Canete A, Navarro S, Bermudez J, Pellin A, Castel V, Llombart-Bosch static Breast Cancer, 1212 A. Angiogenesis in Neuroblastoma: Relationship to Survival Burtness B, see Baselga J and Other Prognostic Factors in a Cohort of Neuroblastoma Burtness BA, see Heath EI Patients, 27 Burton G, see Nabholtz JM Cannistra SA. When Is a ‘Prognostic Factor‘ Really Prognostic? Buter J, see Langer SW (edite tal), 3745 Butera J, see Beckwith C Canto MI, see Heath EI Butera J, Freeman NJ. Hodgkin’s Disease Presenting as a Cystic Neck Cantor SB, see Elting LS Mass, 1150 Caplan AI, see Kog ON Butler P, see List MA Capuron L, Ravaud A, Dantzer R. Early Depressive Symptoms in Butler TW, see von Pawel J Cancer Patients Receiving Interleukin 2 and/or Interferon Butow P, see Meiser B Alfa-2b Therapy, 2143 Buzdar A, see Nabholtz JM Carbone D, see Gandara DR Buzdar AU. Letrozole: Which Dose to Be Used? (correspondence), Cardenas-Cardos R, see Rivera-Luna R 1800 Carducci M, see Kaufman D Buzdar AU, see Breslin TM Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli —see Katz A A, Vinci M, Pinotti G, Lambelet P, Loni C, Verdiani S, De Bydder S, see Elsaleh H Stefano F, Valbonesi M, Corsetti MT. Autografting Followed AUTHOR INDEX by Nonmyeloablative Immunosuppressive Chemotherapy Cellini C, see Zinzani PL and Allogeneic Peripheral-Blood Hematopoietic Stem-Cell Cerrito PB, see McMasters KM Transplantation as Treatment of Resistant Hodgkin’s Disease Cervantes A, see de Gramont A and Non-Hodgkin’s Lymphoma, 3918 Cervek J, see Kaufmann M Carles J, see Bellmunt J Chabbert I, see Yakoub-Agha I Carli P-M, see Chaplain G Chabner BA, see Gutierrez M Carlo-Stella C, see Siena S Chahine A, see Alexandre J Carlson DJ, see McMasters KM Chalmers D, see Barr RD Carlson GA, see Chen EA Chamness GC, see Zellars RC Carlson RW, see Wolden SL Champlin R, see van Besien K Carnot F, see Cabelguenne A Champlin RE, see Seong C-M Caron D, see Morse MA Chan K-Y, see Cheng SH Carpagnano F, see Lorusso V Chanel S, see Camacho LH Carpenter R, see Mokbel K Chang A, see Levitan N Carr KM, Rabinowitz I. Physician Compliance With Warfarin Prophy- Chang E, see Khuri FR laxis for Central Venous Catheters in Patients With Solid Chang H-H, see Chang T-C Tumors, 3665 Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Dowsett M. In Carrére M-O, see Mille D Reply (correspondence), 1601 Carroll PR, see Roach M III Chang JT, see Chang T-C Carroll PR. Prostate Biopsy: A Wealth of Information When Done and Chang M, see Dahl GV Interpreted Correctly (editorial), 1161 Chang P, see Marshall JL Carroll WR, see Bonner JA Chang T-C, Lai C-H, Hong J-H, Hsueh S, Huang K-G, Chou H-H, Carter D, see Smith BD Tseng C-J, Tsai C-S, Chang JT, Lin C-T, Chang H-H, Chao Caruso R, see Madajewicz S P-J, Ng K-K, Tang SG-J, Soong Y-K. Randomized Trial of Caruso RC, see Conley B Neoadjuvant Cisplatin, Vincristine, Bleomycin, and Radical Casadei R, see Bacci G Hysterectomy Versus Radiation Therapy for Bulky Stage IB Casassus P, see Harousseau JL and IIA Cervical Cancer, 1740 Cascinu S, see Graziano F Chao P-J, see Chang T-C Caselli D, Klersy C, de Martino M, Gabiano C, Galli L, Tovo PA, Chaplain G, Milan C, Sgro C, Carli P-M, Bonithon-Kopp C. Increased Arico M for the Italian Register for HIV Infection in Risk of Acute Leukemia After Adjuvant Chemotherapy for Children. Human Immunodeficiency Virus—Related Cancer Breast Cancer: A Population-Based Study, 2836 in Children: Incidence and Treatment Outcome—Report of Chapman RH, see Earle CC the Italian Register, 3854 Chappuis PO, Kapusta L, Bégin LR, Wong N, Brunet J-S, Narod SA, Cassidy J, see de Gramont A Slingerland J, Foulkes WD. Germline BRCA1/2 Mutations see Van Cutsem E and p27*'?! Protein Levels Independently Predict Outcome Cassileth P, see Horning SJ After Breast Cancer, 4045 Cassileth PA, see Hochster HS Chaudri HA, Trunet PF. In Reply (correspondence), 1800 Cassisi NJ, see Mendenhall WM Chauvin F, see Mille D Castellano D, Hitt R, Cortés-Funes H, Romero A, Rodriguez-Peralto Chen AP, see Takimoto CH JL. Radiation Recall Reaction Induced by Gemcitabine, 693 Chen EA, Carlson GA, Coughlin BF, Reed WP Jr, Garb JL, Frank JL. Castel V, see Cafiete A Routine Chest Roentgenography Is Unnecessary in the —see Marco F Work-Up of Stage I and II Breast Cancer, 3503 Castiglione-Gertsch M, see Coates AS; Colleoni M Chen G, see Sandlund JT —see Colleoni M Chen L, see Small EJ —see Crivellari D Chen M-H, see D’Amico AV Castoldi G, see Cuneo A Chen PY, see Kestin LL Catalano G, see Amadori D —see Vicini FA Catalano PJ, see Talamonti MS Cheng JC, see Cheng SH Caty A, see Négrier S Cheng JD, Hitt J, Koczwara B, Schulman KA, Burnett CB, Gaskin DJ, Cavaliere M, see Carella AM Rowland JH, Meropol NJ. Impact of Quality of Life on Cavalli F, see Colleoni M Patient Expectations Regarding Phase I Clinical Trials, 421 —see Crivellari D Cheng L, Slezak J, Bergstralh EJ, Myers RP, Zincke H, Bostwick DG. Cavo M, see Martinelli G Preoperative Prediction of Surgical Margin Status in Patients Cayuela JM, see Morschhauser F With Prostate Cancer Treated by Radical Prostatectomy, Cazenave LA, see Fracasso PM 2862 Cebon J, see Basser RL Cheng SH, Tsai SYC, Yen KL, Jian JJ-M, Chu N-M, Chan K-Y, Tan —see Middleton MR T-D, Cheng JC, Hsieh C-Y, Huang AT. Concomitant Radio- Cederberg D, see Smalley RV therapy and Chemotherapy for Early-Stage Nasopharyngeal Celio L, see Lgnning PE Carcinoma, 2040 Cella D, see Bonomi P Cherlow J, see Thomas PRM see Motzer RJ Cheson B, see Kantarjian HM 4120 AUTHOR INDEX Cheson BD, see Gutierrez M Clerico M, see Postmus PE Cheson BD. The Curious Case of the Baffling Biological (editorial), Cleton FJ, see Weijl NI 2007 Climent MA, see Bellmunt J Chevlen EM, see Mani S Clough KB, see Stoppa-Lyonnet D Chevret S, see Yakoub-Agha I Cnaan A, see Grotzer MA Chiang KY, see Godder KT Coates A, see Middleton MR Chiao J, see Zujewski J Coates AS, Hiirny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Chichino G, see Nasti G Gelber RD, Goldhirsch A for the International Breast Cancer Chilcott F, see Smith IC Study Group. Quality-of-Life Scores Predict Outcome in Child JA, see Davies FE Metastatic but Not Early Breast Cancer, 3768 Chim CS, Choy C, Ooi GC, Chung LP, Wong KK, Liang R. Two Coates AS, see Colleoni M Unusual Lymphomas; Case 2: Pulmonary Intravascular Lym- —see Crivellari D phomatosis, 3733 Cobau CD, see Simpson JF Chim CS, Shek TW, Ooi GC, Liang R. Meningeal Relapse in Cocconi G. Chemotherapy With and Without Anthracycline (corre- Hodgkin’s Disease, 1150 spondence), 1392 Chirikos TN, see Bennett CL Cohen B, see Basser RL Chiusa L, see Pich A Cohen L, see Breslin TM Chlebowski RT, see Hillner BE Cohen MB, see Dreicer R Cho JH, see Kim GE Cohen MH, Johnson JR. Temozolomide for Advanced, Metastatic Chollet P, see Giacchetti S Melanoma (correspondence), 2185 Chompret A, see Delaloge S Cohen MH. Thalidomide in the Treatment of High-Grade Gliomas Chou H-H, see Chang T-C (correspondence), 3453 Chow C, see Conley B Cohen R, see Baselga J —see Zujewski J Cohn SL, see Katzenstein HM Chowdhury AD, see Kirkbride P Cohn SL, London WB, Huang D, Katzenstein HM, Salwen HR, Choy C, see Chim CS Reinhart T, Madafiglio J, Marshall GM, Norris MD, Haber Choy CKW, see Liang R M. MYCN Expression Is Not Prognostic of Adverse Outcome Chrastek J, see Hilden JM in Advanced-Stage Neuroblastoma With Nonamplified Christian M, see Eisenhauer EA MYCN, 3604 Christiansen H, see Poremba C Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, Christiansen NP, see Godder KT Pisansky TM, Willett CG, Hoffman JP, Owen JB, Hanks GE. Christodoulou C, see Briasoulis E Outcome of Patients Receiving Radiation for Cancer of the Christos P, see Vickers A Esophagus: Results of the 1992-1994 Patterns of Care Study, Chu N-M, see Cheng SH 455 Chung EJ, see Kim GE Coiffier B, see Foran JM Chung LP, see Chim CS —see Haioun C Ciccone F, see Zinzani PL —see Tilly H Ciezki J, see Adelstein DJ —see Voog E Cingolani A, Gastaldi R, Fassone L, Pierconti F, Giancola ML, Martini Cokgor I, see Friedman HS M, De Luca A, Ammassari A, Mazzone C, Pescarmona E, Cokgor I, Akabani G, Kuan C-T, Friedman HS, Friedman AH, Gaidano G, Larocca LM, Antinori A. Epstein-Barr Virus Coleman RE, McLendon RE, Bigner SH, Zhao X-G, Garcia- Infection Is Predictive of CNS Involvement in Systemic Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Hern- AIDS-Related Non-Hodgkin’s Lymphomas, 3325 don JE II, Provenzale JM, Zalutsky MR, Bigner DD. Phase I Cinieri S, see Lorusso V Trial Results of Iodine-131—Labeled Antitenascin Monoclo- Cioffi R, see Comella P nal Antibody 81C6 Treatment of Patients With Newly Cirera L. In Reply (correspondence), 3061 Diagnosed Malignant Gliomas, 3862 Cirkel DT, see Smith IE Colabianchi N, see Siminoff LA Cisternino ML, see Lorusso V Colangelo L, see List MA Clahsen PC, see Elkhuizen PHM Colditz GA, see Holmes MD Clark GM, see Eckhardt SG Coleman R, see Paridaens R —see Monsky WL —see Verweij J —see Zellars RC Coleman RE, see Cokgor I Clark P, see von Pawel J Colevas AD. In Reply (correspondence), 1392 Clark T, see Micallef INM Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Clarke A, see Metayer C Price K, Rudenstam C-M, Lindtner J, Collins J, Thiirlimann Clarke KD, see Burstein HJ B, Holmberg S, Veronesi A, Marini G, Goldhirsch A for the Clarke PA, see Waters JS International Breast Cancer Study Group. Early Start of Clavien P, see Morse MA Adjuvant Chemotherapy May Improve Treatment Outcome Clay T, see Morse MA for Premenopausal Breast Cancer Patients With Tumors Not Cleall SP, see von der Maase H Expressing Estrogen Receptors, 584 Cleary KR, see Hoff PM Colleoni M, O’Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thiirli-